New hope for tough cancers: first patients try experimental drug
NCT ID NCT06336148
Summary
This early-stage study tested a new experimental drug called ACTM-838 in patients with advanced solid tumors that had stopped responding to standard treatments. The first part aimed to find the safest and most effective dose, while the second part planned to test that dose in more patients. The trial was terminated early and enrolled only 10 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Hospital, 55 Commercial Road, Site No: 201
Melbourne, Victoria, 3004, Australia
-
Southern Oncology Clinical Research Unit, Level 3, Mark Oliphant Building, 5 Laffer Drive, Site No: 202
Bedford Park, South Australia, 5042, Australia
-
UPMC Hillman Cancer Center, 5115 Centre Ave
Pittsburgh, Pennsylvania, 15232, United States
-
University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave.
Los Angeles, California, 90033, United States
-
Westmead Hospital, Cnr Hawkesbury Road and Darcy Road, Site No: 200
Westmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.